• news.cision.com/
  • Qlife Holding AB/
  • UPDATE: Qlife is emphasizing its strategy to finalize regulatory and Go-To-Market in China, register in Asian countries through partners, and then file for approval in the UK and EU
English

UPDATE: Qlife is emphasizing its strategy to finalize regulatory and Go-To-Market in China, register in Asian countries through partners, and then file for approval in the UK and EU

Report this content

It has been mentioned in the media that Qlife is no longer focused on the EU and other markets. However, as communicated previously, Qlife is focused on finalizing regulatory work in China and roll-out in China together with partner Hipro Biotechnology. Following this, the plan is to register in other Asian countries where partnerships have been established, as well as in the UK and EU.

“As a small MedTech company, we must have an opportunistic view on where we can get our products to market first – the new regulatory framework in the EU has made it extremely resource-demanding to fulfill all regulatory requirements. However, we remain committed to bringing the Egoo Health platform to all markets, especially the Scandinavian countries and Europe in general. We are simply following the pathway that, resource-wise, makes the most sense for us. Eventually, the idea is to be in all global markets,” says Thomas Warthoe, CEO of Qlife.

For more information, please contact: 

Thomas Warthoe
Chief Executive Officer (CEO)
Phone: +45 21 63 35 34
E-mail: tw@egoo.health

About Qlife

Qlife enables advanced clinical-grade biomarker testing at home. The aim is to give ordinary people access to important health data at the clinical-grade level. Egoo Health is an integrated platform, consisting of a small diagnostic device, a blood-to-plasma collector, a disposable capsule that contain test reagents for a specific biomarker and the Egoo smartphone app that operates the system and can share data with health authorities.

Subscribe